bullish
US Hidden Gems | Avid Bioservices: Transitioning Avidly to Pure-Play Biologics CDMO
359 Views20 Aug 2020 08:59
Avid Bioservices Inc (CDMO US) (“Avid”) is a $480mm market-cap US based pure-play biologics CDMO (Contract Development & Manufacturing...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 18-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Avid Bioservices | Up ~2x in 7 Months - Since We Initiated Coverage; Highest Ever Order Backlog10 Mar 2021
- Avid Bioservices: Strong Quarterly Performance Led to 25%+ Re-Rating Last Week. More to Go.07 Dec 2020
- Avid Bioservices: Reports Largest Quarterly Profit Ever; Robust Guidance and Attractive Valuation05 Sep 2020
- Lonza: A Bellwether Biopharma Focused CDMO | At Inflection Point, To Benefit from Ongoing Capex17 Jul 2020
- Wuxi Biologics Placement: Another Pre-Lockup Placement but Past Deals Have Done Well31 Mar 2020
x